Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This study is being performed to prospectively determine whether dacarbazine plus Genasense
is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with
advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit
of normal). LDH is a biomarker strongly associated with improved outcomes in a recent trial
of dacarbazine plus Genasense.